AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6989436
Drug: Late injection
RxNorm normalized name: deoxycholate Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late injection of insulin
Trial: 6989436
Drug: Both injection
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both injection regimens
Trial: 27716673
Drug: PARO robotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARO robotic pet therapy
Trial: 15930028
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg GTP
Trial: 15930028
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg GTP
Trial: 11044540
Drug: beta(2)-adrenergic agonist
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta(2)-adrenergic agonist therapy (clenbuterol)
Trial: 11044540
Drug: physiological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physiological therapy (PT)
Trial: 11044540
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of beta(2)-adrenergic agonist and PT
Trial: 29182498
Drug: Cryogen-cooled monopolar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryogen-cooled monopolar radiofrequency therapy (CMRF) at 90 J/cm2
Trial: 29182498
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (≤1 J/cm2)
Trial: 15533351
Drug: GnRH analogue
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogue plus add-back therapy
Trial: 3277588
Drug: One day
RxNorm normalized name: careone daytime nighttime severe cold and flu KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One day of cefonicid sodium therapy
Trial: 3277588
Drug: Five days
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five days of cefonicid sodium therapy
Trial: 3277588
Drug: Five days
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five days of cefamandole nafate therapy
Trial: 29455298
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg/day) and Exemestane (25 mg/day)
Trial: 25331064
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue injection into the superior rectal artery
Trial: 25442722
Drug: Buffered 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered 2% lidocaine with 1:80,000 epinephrine buffered with 0.18 mL 8.4% sodium bicarbonate
Trial: 25442722
Drug: Nonbuffered 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonbuffered 2% lidocaine with 1:80,000 epinephrine with 0.18 mL sterile distilled water
Trial: 23678970
Drug: Standard Physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Physical Therapy (Standard PT)
Trial: 18446549
Drug: Acupuncture and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and/or interocclusal appliance therapy
Trial: 11061985
Drug: Zafirlukast (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast (40 mg oral)
Trial: 9490579
Drug: 3% gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% gelatin (GEL)
Trial: 3927690
Drug: Indomethacin after
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin after aspirin treatment
Trial: 27003517
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab injection (IRI)
Trial: 11594442
Drug: Caffeinated drink
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeinated drink (100 mg caffeine) consumed by the test group when undeprived on days 1-4, tested when caffeine-deprived on day 5.
Trial: 9767255
Drug: Topical melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical melatonin with vitamins E and C
Trial: 9767255
Drug: Topical vitamin
RxNorm normalized name: vitamin A Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vitamin C alone
Trial: 9767255
Drug: Topical vitamin
RxNorm normalized name: vitamin A Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vitamin E alone
Trial: 9767255
Drug: Topical melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical melatonin alone
Trial: 9767255
Drug: Topical combination
RxNorm normalized name: soap TOPICAL COMBINATION PACKAGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical combination of vitamins E and C
Trial: 8093132
Drug: Isosorbide-5-mononitrate (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (20 mg twice daily)
Trial: 2542193
Drug: Hyperfractionated (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionated (twice daily) radiotherapy (6600 cGy in 60 fractions) + BCNU
Trial: 30307966
Drug: Functionally orientated
RxNorm normalized name: Papaver orientale seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functionally orientated treatment based on the shortened dental arch (SDA) concept
Trial: 24548447
Drug: Estimated drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estimated drug tolerated group (ERCC1 high expression or TOPO I low expression)
Trial: 24548447
Drug: Estimated drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estimated drug sensitive group
Trial: 18440181
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical care (claudication pharmacotherapy)
Trial: 1936511
Drug: Regular gel
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular gel
Trial: 6182412
Drug: Nicardipine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 5 mg, 10 mg, 20 mg (each given three times daily for 1 week)
Trial: 6182412
Drug: Nicardipine (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (higher doses)
Trial: 24419418
Drug: Maintenance pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance pemetrexed (500 mg/m)
Trial: 20931804
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate plus metformin
Trial: 19204305
Drug: Optimal pharmacological
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal pharmacological therapy
Trial: 15304029
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (CT) alone
Trial: 15304029
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (CT) plus low-molecular-weight heparin (LMWH)
Trial: 11236499
Drug: Immunotherapy (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (oral hyposensitization with mite allergens) in combination with ointment containing retinopalmitate and methyluracil
Trial: 11236499
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment combined with the administration of placebo
Trial: 8042821
Drug: Chlorambucil (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorambucil (0.15 mg/kg body weight per day orally) and prednisone (three intravenous pulses of 1 g of methylprednisolone followed by oral prednisone at 0.5 mg/kg per day)
Trial: 8042821
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (750 mg/m2 body surface area once every month for 6 months) and methylprednisolone (three intravenous 1-g pulses)
Trial: 2892771
Drug: Propranolol (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (doses reducing resting heart rate by 25%)
Trial: 2892771
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral vitamin K)
Trial: 19774436
Drug: 8.8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.8 g/day of plant stanols
Trial: 6932209
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg intravaginal PG F2 alpha
Trial: 19432985
Drug: rhAPC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhAPC treatment
Trial: 14695390
Drug: Fixed duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed duration of contrast material injection for 25 seconds (group A)
Trial: 14695390
Drug: Fixed duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed duration of contrast material injection for 35 seconds (group B)
Trial: 14695390
Drug: Fixed injection
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed injection rate of 4.0 mL/sec (group C)
Trial: 11720401
Drug: Pureed peach
RxNorm normalized name: Peach
DrugBank: Peach (DB10552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pureed peach with a thickening agent added
Trial: 11720401
Drug: Pureed peach
RxNorm normalized name: Peach
DrugBank: Peach (DB10552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pureed peach with a thickening agent added and molded to look like peach slices
Trial: 2889416
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg orally every 8 hours
Trial: 22882399
Drug: Guaranteed methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guaranteed methadone treatment admission upon release
Trial: 22882399
Drug: Passive referral
RxNorm normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive referral to substance abuse treatment upon release
Trial: 738078
Drug: Combined preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined preparation of 40 mg frusemide and 600 mg slow-release potassium chloride
Trial: 738078
Drug: Separate tablets
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate tablets of 40 mg frusemide and 600 mg potassium chloride
Trial: 29137091
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer lactate solution (RL)
Trial: 29137091
Drug: Succinylated gelatin
RxNorm normalized name: Succinylated gelatin
DrugBank: Succinylated gelatin (DB16568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylated gelatin injection (Gel)
Trial: 29137091
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline hydroxyethyl starch 40 injection (HS)
Trial: 29137091
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer lactate solution (RL) and Succinylated gelatin injection (Gel)
Trial: 25620547
Drug: Tangerine tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tangerine tomato juice (10 mg lycopene, 94% cis)
Trial: 25620547
Drug: Red tomato
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red tomato juice (10 mg lycopene, 10% cis)
Trial: 16958569
Drug: OROS MPH
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OROS MPH once daily (n = 32)
Trial: 16958569
Drug: IR MPH
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IR MPH three times daily (n = 32)
Trial: 15151265
Drug: Captopril 12.5
RxNorm normalized name: captopril 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 12.5 mg/day
Trial: 15151265
Drug: Ramipril 1.25
RxNorm normalized name: ramipril 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 1.25 mg/day
Trial: 11472790
Drug: Interpersonal psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal psychotherapy (IPT) + fluoxetine
Trial: 9144122
Drug: L. reuteri
RxNorm normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. reuteri
Trial: 2951260
Drug: Fenflumizole 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenflumizole 10 mg b.i.d. for four days followed by 10 mg daily for six days (Group I)
Trial: 2951260
Drug: Fenflumizole 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenflumizole 20 mg b.i.d. for four days followed by 20 mg daily for six days (Group II)
Trial: 23636236
Drug: Zinc (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (20 mg elemental zinc/d)
Trial: 20632667
Drug: Ephedrine 5
RxNorm normalized name: pseudoephedrine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 5 mg (group A; n = 31)
Trial: 12922081
Drug: Low initial
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low initial IgG antibody concentrations against pertussis toxin
Trial: 8642163
Drug: 10 mcg
RxNorm normalized name: D400, 10 mcg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mcg HBs vaccine (Recombivax, Merck, Sharp and Dohme)
Trial: 8642163
Drug: 12 mcg
RxNorm normalized name: Thyrox 112 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mcg PreS2 + S vaccine
Trial: 8642163
Drug: 24 mcg
RxNorm normalized name: Amitiza 24 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mcg PreS2 + S vaccine
Trial: 1737453
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition plus human albumin 25 g/L as a continuous infusion
Trial: 1737453
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (control)
Trial: 3896964
Drug: +cyanidanol-3 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +cyanidanol-3 (3 g daily)
Trial: 22399076
Drug: BMS group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS group therapy
Trial: 15060238
Drug: No-treatment standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment standard care (control group)
Trial: 3545461
Drug: L-Dopa plus
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-Dopa plus benserazide
Trial: 31808298
Drug: Low-dose SAR425899
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose SAR425899 (0.03, 0.06 and 0.09 mg)
Trial: 31808298
Drug: High-dose SAR425899
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose SAR425899 (0.06, 0.12 and 0.18 mg)
Trial: 31808298
Drug: Low-dose SAR425899
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose SAR425899
Trial: 31808298
Drug: High-dose SAR425899
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose SAR425899
Trial: 30183438
Drug: New adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: New adalimumab formulation
Trial: 30183438
Drug: Existing adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Existing adalimumab formulation
Trial: 19878390
Drug: Retin-OX+ lotion
RxNorm normalized name: tretinoin Topical Lotion [Retin-A]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retin-OX+ lotion applied on one side of the face for 8 weeks
Trial: 15201246
Drug: Spironolactone 12.5‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 12.5‐50 mg/24 hours for three months
Trial: 10914827
Drug: Anterior Resection
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior Resection (AR) for lower third rectal tumours
Trial: 3582710
Drug: Hexyl nicotinate
RxNorm normalized name: Hexyl nicotinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexyl nicotinate lotion applied topically
Trial: 30146421
Drug: 1 or
RxNorm normalized name: G-1 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or more missed treatments in the 4 months before enrollment
Trial: 30146421
Drug: Countries with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Countries with a 4-month missed treatment risk > 5%
Trial: 30146421
Drug: Missed treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Missed treatments
Trial: 20364681
Drug: Nitrosorbid (NS)
RxNorm normalized name: Dinitrosorbide
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrosorbid (NS) and hydrogen sulfide‐based balneotherapy (HSB) applied alone or in combination
Trial: 20364681
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HSB and NS
Trial: 15901766
Drug: Higher hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher hemoglobin target (13.5 to 14.5 g/dl)
Trial: 15901766
Drug: Lower hemoglobin
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower hemoglobin target (9.5 to 11.5 g/dl)
Trial: 8067231
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg morphine (intraarticular injection)
Trial: 8067231
Drug: Saline (intraarticular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (intraarticular injection)
Trial: 24044687
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei Shirota (LcS) probiotic drink, given once daily for the duration of the antibiotic course and continued for 7 days thereafter.
Trial: 22289130
Drug: Medication (Fluoxetine)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Fluoxetine)
Trial: 20053950
Drug: Treatment 3
RxNorm normalized name: Canesten Clotrimazole Thrush Treatment 3 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 3
Trial: 20053950
Drug: Treatment 4
RxNorm normalized name: Acne Treatment 4 % - 5 % Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 4
Trial: 16023710
Drug: Lidcombe Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidcombe Program (LP) treatment
Trial: 16023710
Drug: Demands and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demands and Capacities Model (DCM) treatment
Trial: 9082223
Drug: Intraperitoneal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal infusion of bupivacaine
Trial: 9082223
Drug: Placebo (physiologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (physiologic solution)
Trial: 6707202
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g protein/kg ideal body weight
Trial: 6707202
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g protein/kg ideal body weight plus 0.7 g carbohydrate/kg ideal body weight
Trial: 26955678
Drug: WZR (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WZR (oral administration)
Trial: 20650361
Drug: Drug/device therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug/device therapies
Trial: 11772264
Drug: Novel therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel therapies and vaccines for meningococcal disease
Trial: 8488226
Drug: 5-session, time-limited
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-session, time-limited therapy (n = 16)
Trial: 8488226
Drug: Time-unlimited therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-unlimited therapy (n = 15)
Trial: 30256537
Drug: Rolapitant at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rolapitant at the highest safe dose (720 mg)
Trial: 30256537
Drug: Rolapitant at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rolapitant at presumed therapeutic dose (180 mg)
Trial: 20177420
Drug: Irinotecan and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan and 5-FU treatment in patients with ABCB1 3435 T/T genotype
Trial: 20177420
Drug: Irinotecan and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan and 5-FU treatment in patients with UGT1A1(*)28/(*)28 genotype
Trial: 20177420
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with toxicity during the first two cycles of treatment
Trial: 19244090
Drug: Ethanol solution
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol solution (12.5%)
Trial: 16516118
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of handheld FOB, misting, and end-tidal carbon dioxide concentration (ETCO2)
Trial: 9419927
Drug: Preventive health
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive health care strategies (not specified dosage or duration)
Trial: 9419927
Drug: Preventive Medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive Medicine profile